Table 1.

Evaluation of SU11248 combined with docetaxel compared with monotherapies against 100-mm3 established human breast cancer MX-1 in athymic mice

AgentaDose (mg/kg)Mean tumor volume (mm3 ± SEM) (days)%T/Cb (days)
P-value

Mean day for tumor to reach 500 mm3

TCb (days)
ControlN/A748 ± 97 (16)N/AN/A10
SU1124840492 ± 129 (16)34 (16)NS188
566 ± 156 (20)53 (20)0.02
Docetaxel51204 ±148 (16)0 (16)NS90
Docetaxel10343 ± 91 (16)60 (16)0.0052919
Docetaxel1541 ± 12 (16)95 (16)<0.00015444
759 ± 181 (58)
SU11248 + docetaxel40 + 5221 ± 26 (16)70 (16)<0.00014232
vs. SU11248: 55 (16)0.06 (NS)
vs. Docetaxel: 82 (16)<0.0001
vs. SU11248: 55 (27)0.04
SU11248 + docetaxel40 + 10141 ± 34 (16)81 (16)<0.00018575
122 ± 34 (20)vs. SU11248: 71 (16) 0.02
vs. Docetaxel: 59 (16)0.05
vs. SU11248: 78 (20)0.01
vs. Docetaxel: 62 (20)0.04
vs. Docetaxel: 77 (37)0.005
SU11248 + Docetaxel40 + 15140 ± 92 (58)vs. Docetaxel: 82 (58)0.0089181
  • a SU11248 given p.o. once daily to study end; docetaxel given i.v. once weekly for 3 weeks.

  • b T/C, tumor growth inhibition, where T is the mean tumor volume of the treated group and C is the mean tumor volume of the control group on the designated day. TC, tumor growth delay, median time (days) for the treated tumors to reach 500-mm3 volume minus the median time for control group to reach 500 mm3 in volume.